GATC Health Named a Top Innovation by The Scientist
The company's Derisq platform received an award in the Emerging Startup Technologies category.
Updated on Sept. 29, 2026 in Biotech
Live Poll
Do you trust artificial intelligence to improve the safety and accuracy of new drug discovery?
The Scientist recognized GATC Health's Derisq platform as a 2026 Top Innovation. The Irvine-based biotechnology firm secured the honor in the Emerging Startup Technologies category.
Why it matters
The award highlights technologies that demonstrate the potential to significantly advance healthcare, biotechnology, and life sciences research. The selection was made by an independent panel of life sciences experts.
Evaluations by the University of California, Irvine show Derisq achieves 91% specificity for off-target risks and 86% sensitivity for target activation. The platform utilizes in silico modeling to analyze drug candidates.
The players
GATC Health
An Irvine-based biotechnology company that specializes in using advanced AI for drug discovery and healthcare research.
The Scientist
A long-standing publication and industry resource that has provided coverage of the life sciences sector for 40 years.
The details
Derisq operates on the proprietary Operon AI platform to generate critical insights into the safety and efficacy of potential drugs. The recognition validates the tool's performance in early-stage pharmaceutical development.
Timeline
The Scientist established its Top Innovations competition in 2008.
Winners for the 2026 Top Innovation awards were announced on September 29, 2026.
The Tech Race
The use of in silico modeling marks a shift away from traditional, resource-heavy wet lab drug discovery methods toward faster, AI-driven simulations. This positions GATC Health within an expanding sector of companies aiming to reduce the timeline of pharmaceutical development.
This innovation potentially accelerates the arrival of new medical treatments by making drug development more efficient. Users may benefit from future pharmaceutical breakthroughs that are identified and validated with higher precision.
The takeaway
AI-driven modeling represents a major advancement in identifying safe and effective drug candidates. Investors and researchers should monitor how such technologies continue to perform as they transition from development tools to clinical application.
Further reading
Learn more about the latest developments in the sector on the Biotech page.
Source note: This article includes information reported by The Manila times.
Live Poll
Do you trust artificial intelligence to improve the safety and accuracy of new drug discovery?
